8-K: Nurix Therapeutics Reports Q4 2025 Results, Advances Pipeline

Nurix Therapeutics announced its financial results for the fiscal quarter and year ended November 30, 2025, highlighting significant progress in its clinical programs, including the initiation of a pivotal study for bexobrutideg in CLL and a strengthened balance sheet.

Summary

• Reported financial results for the fiscal quarter and year ended November 30, 2025.
• Initiated the DAYBreak registrational program for bexobrutideg in relapsed/refractory chronic lymphocytic leukemia (CLL).
• Presented Phase 1 results for bexobrutideg at ASH 2025, demonstrating an 83% objective overall response rate (ORR) and a median progression-free survival (PFS) of 22.1 months in r/r CLL.
• Presented differentiated preclinical data for the IRAK4 degrader GS-6791 in collaboration with Gilead.
• Strengthened the balance sheet with $592.9 million in cash, cash equivalents, and marketable securities as of November 30, 2025.
• Completed a $250.0 million underwritten registered offering of common stock in October 2025.
• Appointed Roger Dansey, M.D., to the Board of Directors in November 2025.
• Total revenue for fiscal year 2025 was $84.0 million, an increase from $54.5 million in fiscal year 2024, primarily due to $30 million in license revenue from Sanofi.
• Net loss for fiscal year 2025 was $264.5 million, or ($3.05) per share, compared to $193.6 million, or ($2.88) per share, in fiscal year 2024.

Sentiment

Score: 7

Explanation: While financial losses increased due to R&D acceleration, the company made significant clinical progress with bexobrutideg entering pivotal trials, reported strong Phase 1 data, and successfully raised $250 million, strengthening its financial position for future development. The clinical advancements and strategic collaborations outweigh the increased burn rate for a clinical-stage biopharmaceutical company.

Positives

• Initiation of the DAYBreak pivotal Phase 2 single-arm study for bexobrutideg in r/r CLL, designed to support a potential Accelerated Approval submission.
• Compelling Phase 1 clinical data for bexobrutideg in r/r CLL, showing an 83.0% objective response rate (ORR), including two complete responses, with a median progression-free survival (PFS) of 22.1 months and a median duration of response of 20.1 months.
• Bexobrutideg demonstrated a consistent safety profile across dose levels with no dose-limiting toxicities, systemic fungal infections, or Grade 4 infections observed.
• Encouraging activity of bexobrutideg in Waldenström Macroglobulinemia (WM) with a 75.0% ORR, including three very good partial responses, and durable clinical benefit.
• Strengthened balance sheet with $592.9 million in cash, cash equivalents, and marketable securities as of November 30, 2025.
• Successful completion of a $250.0 million underwritten registered offering in October 2025, significantly bolstering capital for pipeline execution.
• Achieved $30 million in license revenue from two Sanofi license extensions during fiscal year 2025.
• Achieved research milestones totaling $7.0 million from Sanofi and $5.0 million from Pfizer, and a clinical milestone of $5 million from Gilead in fiscal year 2025.
• Appointment of Roger Dansey, M.D., to the Board of Directors, adding deep expertise in oncology research and development.
• Preclinical data for IRAK4 degrader GS-6791 (partnered with Gilead) demonstrated potent and sustained degradation of IRAK4, leading to robust inhibition of IL-1 and IL-36 signaling pathways.
• NX-1607 (CBL-B Inhibitor) showed dose-dependent target engagement, peripheral immune activation, and evidence of single-agent anti-tumor activity, including a confirmed partial response in heavily pretreated patients.

Negatives

• Net loss for the fiscal year ended November 30, 2025, increased to $264.5 million or ($3.05) per share, compared to $193.6 million or ($2.88) per share for the prior fiscal year.
• Research and development expenses significantly increased to $316.9 million for fiscal year 2025, up from $221.6 million in fiscal year 2024, primarily due to accelerated clinical and contract manufacturing costs.
• General and administrative expenses increased to $52.7 million for fiscal year 2025, up from $45.9 million in fiscal year 2024, mainly due to increased compensation and personnel costs.
• Revenue from collaborations with Sanofi and Gilead decreased as the initial research term for certain drug targets concluded.

Risks

• Uncertainties related to the timing and results of preclinical studies and clinical trials.
• Whether Nurix will be able to fund development activities and achieve development goals.
• Uncertainties related to the timing and receipt of payments from collaboration partners, including milestone payments and royalties on future product sales.
• The impact of global business, political, and macroeconomic conditions, cybersecurity events, instability in the banking system, and global events on Nurix's business, clinical trials, financial condition, liquidity, and results of operations.
• Whether Nurix will be able to protect its intellectual property.
• Whether Nurix will be able to advance its drug candidates, obtain regulatory approval, and ultimately commercialize them.

Future Outlook

Nurix plans to continue enrollment in the DAYBreak pivotal Phase 2 study for bexobrutideg in r/r CLL, aiming for potential Accelerated Approval. A global randomized confirmatory Phase 3 trial for bexobrutideg is planned for the first half of 2026 to support full approval, comparing it to pirtobrutinib. The company also continues enrollment in Phase 1a/1b trials for bexobrutideg in B cell malignancies and is preparing for a potential autoimmune IND in 2026. Further advancement of zelebrudomide and NX-1607 clinical trials is expected, along with continued progress in strategic collaborations with Gilead, Sanofi, and Pfizer, anticipating substantial research collaboration milestones throughout 2026.

Management Comments

• "The fourth quarter marked a pivotal inflection point for Nurix as we initiated the DAYBreak registrational program for bexobrutideg and strengthened our balance sheet to support execution across our pipeline."
• "With regulatory alignment on Phase 2 dose, compelling Phase 1 clinical data in CLL, and the continued advancement of our autoimmune and immuno-oncology programs, we believe we are well positioned to deliver the benefits of degrader-based medicines to significant populations of patients in need of new therapies."

Industry Context

Nurix Therapeutics operates in the highly competitive biopharmaceutical sector, specifically focusing on targeted protein degradation, a cutting-edge area of drug design. The advancement of bexobrutideg, a BTK degrader, positions Nurix against existing covalent and non-covalent BTK inhibitors in the CLL and WM markets, aiming to address limitations of current therapies through its differentiated mechanism of action. The collaboration with major pharmaceutical companies like Gilead, Sanofi, and Pfizer validates its platform and pipeline, aligning with industry trends of strategic partnerships for complex drug development. The focus on autoimmune and immuno-oncology programs also reflects broader industry efforts to expand targeted therapies beyond traditional oncology.

Comparison to Industry Standards

• Bexobrutideg's Phase 1 data in r/r CLL (83% ORR, 22.1 months PFS) demonstrates durable therapeutic effects, potentially offering a best-in-class profile compared to existing BTK inhibitors like ibrutinib, acalabrutinib, zanubrutinib (covalent BTKi), and pirtobrutinib (non-covalent BTKi), especially in heavily pretreated populations.
• The company's strategy to overcome limitations of existing BTK inhibitors by catalytically degrading the BTK protein, eliminating both kinase and scaffolding functions, represents a differentiated approach in the competitive BTK inhibitor landscape.
• The planned Phase 3 trial comparing bexobrutideg monotherapy to pirtobrutinib in r/r CLL patients who have progressed after prior BTK inhibitor therapy directly positions it against a key competitor in a high unmet need population.
• The preclinical data for IRAK4 degrader GS-6791, showing potent and sustained degradation and robust inhibition of IL-1 and IL-36 signaling, supports its differentiated potential compared with kinase inhibition alone in autoimmune and inflammatory diseases, a field where many kinase inhibitors are being developed.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value through pipeline advancement and strengthened balance sheet, but also increased net losses and R&D expenses. The $250 million offering diluted existing shares but provided capital for accelerated development.
• Patients: Potential for new, differentiated therapeutic options, especially for those with relapsed/refractory CLL and WM, and future treatments for autoimmune and immuno-oncology indications.
• Employees: Continued investment in R&D and pipeline expansion suggests stable or growing employment opportunities.
• Collaboration Partners (Gilead, Sanofi, Pfizer): Continued progress in partnered programs and achievement of milestones reinforce the value of these collaborations.

Next Steps

• Continue enrollment and execution of the DAYBreak pivotal Phase 2 single-arm study (NCT07221500) of bexobrutideg in r/r CLL.
• Initiate a global randomized confirmatory Phase 3 trial for bexobrutideg in the first half of 2026, comparing it to pirtobrutinib in r/r CLL.
• Continue enrollment in the NX-5948-301 Phase 1a/1b clinical trial of bexobrutideg in B cell malignancies.
• Enroll a Phase 1b cohort for bexobrutideg in patients with CLL and autoimmune hemolytic anemia.
• Conduct necessary Phase 1 healthy volunteer studies to support a potential autoimmune IND for bexobrutideg in 2026.
• Continue dose escalation study within the current Phase 1a/1b trial for zelebrudomide using the chirally controlled drug product.
• Continue evaluating NX-1607 in an ongoing Phase 1 trial in adults across a range of oncology indications, including thorough investigation of dose and schedule.
• Continue to advance strategic collaborations with Gilead, Sanofi, and Pfizer, anticipating substantial research collaboration milestones throughout 2026.
• Provide additional preclinical, clinical, and program updates throughout 2026 to key audiences like EHA, ESMO, SITC, and ASH.

Key Dates

Recommendation

Nurix Therapeutics has demonstrated significant clinical progress with bexobrutideg entering pivotal trials and showing compelling Phase 1 data, which are strong positive indicators for a clinical-stage biopharmaceutical company. The successful $250 million capital raise has substantially strengthened the balance sheet, providing runway for accelerated development. However, the company continues to incur substantial and increasing net losses and R&D expenses, which is typical for this stage but warrants caution. The stock is a 'hold' for investors who are comfortable with the inherent risks of clinical-stage biotech, given the promising pipeline advancements balanced against the ongoing cash burn and the long path to potential commercialization.

Keywords

Nurix Therapeutics, NRIX, biopharmaceutical, targeted protein degradation, bexobrutideg, NX-5948, CLL, chronic lymphocytic leukemia, Waldenström Macroglobulinemia, WM, IRAK4 degrader, GS-6791, Gilead, NX-1607, CBL-B inhibitor, immuno-oncology, zelebrudomide, BTK inhibitor, cancer, autoimmune diseases, clinical trials, financial results, Q4 2025, drug development, oncology, hematology